Doramapimod (BIRB 796)

製品コードS1574 バッチS157403

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C31H37N5O3
分子量 527.66 CAS No. 285983-48-4
Solubility (25°C)* 体外 DMSO 100 mg/mL (189.51 mM)
Ethanol 100 mg/mL (189.51 mM)
Water Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.
in vitro

Doramapimod (BIRB 796) shows no significant inhibition to ERK-1, SYK, IKK2β, ZAP-70, EGF receptor kinase, HER2, protein kinase A (PKA), PKC, PKC-α, PKC-β (I and II) and PKC-γ. It greatly improves binding affinity by forming a hydrogen bond between the morpholine oxygen and the ATP-binding domain of p38α. This compound represents one of the most potent and slowest dissociating inhibitors against human p38 MAP kinase now known. [1]

It potently inhibits c-Raf-1 and Jnk2α2 with IC50 of 1.4 and 0.1 nM, respectively. [2]

It also inhibits the activity and the activation of SAPK3/p38γ at a higher concentration than it does in p38α. It blocks the stress-induced phosphorylation of the scaffold protein SAP97, which is a physiological substrate of SAPK3/p38γ. It blocks JNK1/2 activation and activity in HEK293 cells, while not inhibits the activation and activity of ERK1/ERK2 in Hela cells. Moreover, the binding of this compound to the p38 MAPKs or JNK1/2 is impairing their phosphorylation by the upstream kinase MKK6 or MKK4 rather than enhancing their dephosphorylation. [3]

It blocks baseline and upregulation of p38 MAPK and Hsp27 phosphorylation, thereby enhancing cytotoxicity and caspase activation. It downregulates IL-6 and VEGF secretion in BMSCs triggered by TNF-α and TGF-β1. [4]

It has a pyrazole scaffold that places a lipophilic t-butyl group into the lower selectivity site and a tolyl ring into the upper selectivity site. It also inhibits B-Raf and Abl with IC50 of 83 nM and 14.6 μM, respectively. [5]
in vivo

Doramapimod (BIRB 796) (30 mg/kg) inhibits 84% of TNF-α in LPS-stimulated mice and demonstrates efficacy in a mouse model of established collagen-induced arthritis. [1]

It has good pharmacokinetic performance even after oral administration in mice. [2]
特徴 The first p38 MAPK inhibitor to be tested in a phase III clinical trial.

プロトコル(参考用のみ)

キナーゼアッセイ Procedures for the THP-1 cellular assay for inhibition of LPS-stimulated TNF-α production
THP-1 cells are preincubated in the presence and absence of Doramapimod (BIRB 796) for 30 min. The cell mixture is stimulated with LPS (1 μg/mL final) and incubation continued overnight (18−24 hours) as above. Supernatant is analyzed for human TNF-α by a commercially available ELISA. Data are combined and analyzed by nonlinear regression using a three parameter logistic model to obtain an EC50 value. It is analyzed in each experiment and the 95% confidence intervals for the EC50 are between 16 and 22 nM.
細胞アッセイ 細胞株 Cell-free assays
濃度
反応時間
実験の流れ
動物実験 動物モデル Collagen-induced arthritis in female Balb/c mice
投薬量 1 mg/kg (intravenous) or 10 mg/kg (oral)
投与方法 Intravenous injection or by oral

参考

  • https://pubmed.ncbi.nlm.nih.gov/11896401/
  • https://pubmed.ncbi.nlm.nih.gov/12086485/
  • https://pubmed.ncbi.nlm.nih.gov/15755732/
  • https://pubmed.ncbi.nlm.nih.gov/17173546/
  • https://pubmed.ncbi.nlm.nih.gov/20621496/
  • https://pubmed.ncbi.nlm.nih.gov/14561087/

カスタマーフィードバック

Data from [Data independently produced by Int J Cancer, 2014, 134(3), 575-86]

Data from [Data independently produced by Biochem J, 2014, 449(2), 497-506]

Data from [Data independently produced by Blood, 2012, 119(26), 6255-8]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer [ Nat Cancer, 2025, 6(2):259-277] PubMed: 39820127
p38 mediated ACSL4 phosphorylation drives stress-induced esophageal squamous cell carcinoma growth through Src myristoylation [ Nat Commun, 2025, 16(1):3319] PubMed: 40195298
Heparan sulfate regulates myofibroblast heterogeneity and function to mediate niche homeostasis during alveolar morphogenesis [ Nat Commun, 2025, 16(1):1834] PubMed: 39979343
Inhibition of DEK restores hematopoietic stem cell function in Fanconi anemia [ J Exp Med, 2025, 222(3)e20241248] PubMed: 39836085
Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts [ Cell Rep Med, 2025, S2666-3791(25)00430-6] PubMed: 40975064
Tumor cell-released autophagosomes (TRAPs) induce PD-L1-decorated NETs that suppress T-cell function to promote breast cancer pulmonary metastasis [ J Immunother Cancer, 2024, 12(6)e009082] PubMed: 38926151
Vitamin D3 inhibits p38 MAPK and senescence-associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing [ Aging Cell, 2024, e14093.] PubMed: 38287646
Lack of p38 activation in T cells increases IL-35 and protects against obesity by promoting thermogenesis [ EMBO Rep, 2024, 10.1038/s44319-024-00149-y] PubMed: 38730210
Cetylpyridinium chloride triggers paraptosis to suppress pancreatic tumor growth via the ERN1-MAP3K5-p38 pathway [ iScience, 2024, 27(8):110598] PubMed: 39211547
Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway [ Biochem J, 2024, 481(6):405-422] PubMed: 38381045

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。